Officials laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, ...

At an event on Monday, the agency officially unveiled long-awaited draft guidance meant to help speed the development of bespoke treatments for extremely rare diseases.

The Food and Drug Administration aims to evaluate treatments for rare diseases based on plausible evidence that they would work — without requiring a clinical trial first.

A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...

One of the most promising is its cardiovascular disease therapy candidate CTX310, a single-treatment gene therapy that has ...

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...

Mr. President, we thank you so much for your time. We really do appreciate it. PRESIDENT DONALD TRUMP: Thank you very much. TOM LLAMAS: As you know, Americans are getting ready for the Super Bowl — ...

We may receive commissions from some links to products on this page. Promotions are subject to availability and retailer terms. The good news is that mortgage interest rates, overall, declined in 2025 ...